New combo pill attack aims to control blood cancers
NCT ID NCT07609862
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried other treatments will take part. This is not a cure; patients may need ongoing therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Can a chemo-free cocktail tame mantle cell lymphoma?
- Can a Three-Drug cocktail replace chemo for follicular lymphoma?